Canada's federal Health Minister, Allan Rock, is to propose thatcost-effectiveness should become a third criterion, in addition to safety and efficacy, in the approval of new drugs.
Mr Rock said he would propose this at a meeting in September with the provincial health ministers, held to examine ways of dealing with the nation's soaring prescription drug reimbursement costs, reports the Montreal Gazette. Adoption of this approach would involve the establishment of an advisory group, similar to one set up in Australia, which would conduct cost-benefit analyses on newly-approved non-innovative drugs and present its findings to the provinces, which would then, on the strength of this evidence, decide whether or not to include the product on their formularies.
The report notes that a major problem for the provincial formularies' finances in recent years has been the fact that, once one province decides to list a "me-too" drug on its formulary, all the others come under strong pressure to follow suit. However, it adds, federal health officials have stressed that there are no plans to change the approval process so as to deny such products access to the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze